{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:22:50Z","timestamp":1794475370821,"version":"4.9.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1097\/hjh.0b013e3283638b1a","type":"journal-article","created":{"date-parts":[[2013,8,29]],"date-time":"2013-08-29T13:48:03Z","timestamp":1377784083000},"page":"2094-2102","source":"Crossref","is-referenced-by-count":128,"title":["Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus"],"prefix":"10.1097","volume":"31","author":[{"given":"Christina S.","family":"Oxlund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan E.","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Tarnow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Schousboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe","family":"Gram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ib A.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-25-20210208","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11886-011-0236-8","article-title":"Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes.","volume":"14","author":"Reboldi","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"R2-25-20210208","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-138-7-200304010-00018","article-title":"Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care.","volume":"138","author":"Vijan","year":"2003","journal-title":"Ann Intern Med"},{"key":"R3-25-20210208","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","article-title":"Diabetes and hypertension: the bad companions.","volume":"380","author":"Ferrannini","year":"2012","journal-title":"Lancet"},{"key":"R4-25-20210208","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/hr.2011.6","article-title":"Are blood pressure and diabetes additive or synergistic risk factors Outcome in 8494 subjects randomly recruited from 10 populations.","volume":"34","author":"Shestedt","year":"2011","journal-title":"Hypertens Res"},{"key":"R5-25-20210208","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/fampra\/cmr027","article-title":"Treatment of 5413 hypertensive patients: a cross-sectional study.","volume":"28","author":"Paulsen","year":"2011","journal-title":"Fam Pract"},{"key":"R6-25-20210208","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","article-title":"Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document.","volume":"27","author":"Mancia","year":"2009","journal-title":"J Hypertens"},{"key":"R7-25-20210208","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","article-title":"Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.","volume":"57","author":"de la Sierra","year":"2011","journal-title":"Hypertension"},{"key":"R8-25-20210208","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jash.2008.08.001","article-title":"Prevalence, awareness, and control of arterial hypertension in Denmark.","volume":"3","author":"Kronborg","year":"2009","journal-title":"J Am Soc Hypertens"},{"key":"R9-25-20210208","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of hypertension; and European Society of Cardiology.","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"R10-25-20210208","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"R11-25-20210208","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cjca.2012.03.010","article-title":"3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update.","volume":"28","author":"Clark","year":"2012","journal-title":"Can J Cardiol"},{"key":"R12-25-20210208","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients.","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"R13-25-20210208","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","article-title":"Uncontrolled and apparent treatment resistant hypertension in the United States, 1988-2008.","volume":"124","author":"Egan","year":"2011","journal-title":"Circulation"},{"key":"R14-25-20210208","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/07420528.2012.701135","article-title":"Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring.","volume":"30","author":"Rios","year":"2013","journal-title":"Chronobiol Int"},{"key":"R15-25-20210208","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.amjhyper.2005.05.014","article-title":"Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant and true resistant hypertension.","volume":"18","author":"Pierdomenico","year":"2005","journal-title":"Am J Hypertens"},{"key":"R16-25-20210208","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ajh.2011.245","article-title":"Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.","volume":"25","author":"Shibata","year":"2012","journal-title":"Am J Hypertens"},{"key":"R17-25-20210208","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","article-title":"Aldosterone and refractory hypertension: a prospective cohort study.","volume":"19","author":"Sartori","year":"2006","journal-title":"Am J Hypertens"},{"key":"R18-25-20210208","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.","volume":"57","author":"Vaclavik","year":"2011","journal-title":"Hypertension"},{"key":"R19-25-20210208","first-page":"75","article-title":"Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.","volume":"22","author":"Abolghasmi","year":"2011","journal-title":"Saudi Kidney Dis Transpl"},{"key":"R20-25-20210208","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","article-title":"Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.","volume":"31","author":"Colussi","year":"2012","journal-title":"J Hypertens"},{"key":"R21-25-20210208","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00126097-200008000-00006","article-title":"Validation of AD UA-767 device for the self- measurement of blood pressure.","volume":"5","author":"Rogoza","year":"2000","journal-title":"Blood Press Monit"},{"key":"R22-25-20210208","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/MBP.0b013e328351d4a4","article-title":"Yip, Hung-Kwan SO, Tomlinson B, Wong SN, Sung RY. Validation of AD TM-2430 upper-arm blood pressure monitor for ambulatory blood pressure monitoring in children and adolescents, according to the British Hypertension Society protocol.","volume":"17","year":"2012","journal-title":"Blood Press Monit"},{"key":"R23-25-20210208","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/01.hjh.0000163132.84890.c4","article-title":"on behalf of the European Society of Hypertension Working Group on Blood Pressure MonitoringPractice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement.","volume":"23","author":"OBrien","year":"2005","journal-title":"J Hypertens"},{"key":"R24-25-20210208","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in modification of diet in renal disease study equation for estimating glomerular filtration rate.","volume":"145","author":"AS Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"R26-25-20210208","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension.","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu Rev Med"},{"key":"R27-25-20210208","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension.","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"R28-25-20210208","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jash.2010.10.001","article-title":"The effect of low-dose spironolactone on resistant hypertension.","volume":"4","author":"Engbaek","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"R29-25-20210208","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","article-title":"Low-dose spironolactone in the management of resistant hypertension: a surveillance study.","volume":"25","author":"Lane","year":"2007","journal-title":"J Hypertens"},{"key":"R30-25-20210208","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.amjhyper.2005.11.016","article-title":"Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension.","volume":"19","author":"Sharabi","year":"2006","journal-title":"Am J Hypertens"},{"key":"R31-25-20210208","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","article-title":"Efficacy of spironolactone therapy in patients with true resistant hypertension.","volume":"55","author":"de Souza","year":"2010","journal-title":"Hypertension"},{"key":"R32-25-20210208","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/HYPERTENSIONAHA.109.133900","article-title":"Predictive role of the nighttime blood pressure.","volume":"57","author":"Hansen","year":"2011","journal-title":"Hypertension"},{"key":"R33-25-20210208","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts).","volume":"28","author":"Graham","year":"2007","journal-title":"Eur Heart J"},{"key":"R34-25-20210208","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.110.016337","article-title":"Blood pressure targets in subjects with type 2 diabetes mellitusimpaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.","volume":"123","author":"Bangalore","year":"2011","journal-title":"Circulation"},{"key":"R35-25-20210208","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2337\/dc11-1827","article-title":"Intensive Blood Pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial.","volume":"35","author":"Barzilay","year":"2012","journal-title":"Diabetes care"},{"key":"R36-25-20210208","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1161\/HYPERTENSIONAHA.111.00289","article-title":"Masked hypertension in diabetes mellitus.","volume":"61","author":"Franklin","year":"2013","journal-title":"Hypertension"},{"key":"R37-25-20210208","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/HJH.0b013e3283469976","article-title":"Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: A metaanalysis in 73913 patients.","volume":"29","author":"Reboldi","year":"2011","journal-title":"J Hypertens"},{"key":"R38-25-20210208","first-page":"1575","article-title":"2 diabetes mellitus.","volume":"362","year":"2010","journal-title":"N Engl J Med"},{"key":"R39-25-20210208","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes care"},{"key":"R40-25-20210208","first-page":"1575","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vacular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial.","volume":"371","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"R41-25-20210208","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension.","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"R42-25-20210208","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.","volume":"376","author":"Esler","year":"2010","journal-title":"Lancet"},{"key":"R43-25-20210208","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patiants with resistant hypertension: results from the double blind, randomized, placebo-controlled Rheos pivotal trial.","volume":"58","author":"Bisognano","year":"2011","journal-title":"Am Coll Cardiol"},{"key":"R44-25-20210208","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","article-title":"Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.","volume":"30","author":"Bobrie","year":"2012","journal-title":"J Hypertens"},{"key":"R45-25-20210208","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/HYPERTENSIONAHA.111.190637","article-title":"Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate.","volume":"59","author":"Peterzan","year":"2012","journal-title":"Hypertension"},{"key":"R46-25-20210208","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/jhh.2010.108","article-title":"How common is true resistant hypertension.","volume":"25","author":"Bunker","year":"2011","journal-title":"J Hum Hypertens"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0b013e3283638b1a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:41:41Z","timestamp":1621885301000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201310000-00025"}},"subtitle":["a double blind randomized clinical trial"],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e3283638b1a","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}